Biblio Discovery — Demo Discovery Service

72 hasil untuk "Frauke Zipp"

Menampilkan 1–20 · 0,81 detik · RSS

  1. Artikel Jurnal

    Preventing disease progression in multiple sclerosis—insights from large real-world cohorts

    Sinah Engel; Frauke Zipp

    Genome Medicine, Vol. 14 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Multiple sclerosis is a chronic neuroinflammatory disease with a highly heterogeneous disease course. Preventing lasting disability requires early identification of persons at risk and novel approaches towards patient stratification for personalized treatment decisions. In this comment, we…

  2. Artikel Jurnal

    Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement

    Katrin Pape; Falk Steffen; Frauke Zipp dkk.

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 6 · 2020 · Inggris · DOAJ Scopus

    Background As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. Objective We aimed to assess the spectrum and intake…

  3. Artikel Jurnal Teks lengkap

    The potential of serum neurofilament as biomarker for multiple sclerosis

    Stefan Bittner; Jiwon Oh; Eva Havrdová dkk.

    Brain · 2021 · Inggris · OpenAlex Scopus

    Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and…

  4. Artikel Jurnal

    Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders

    Tobias Brummer; Tobias Ruck; Sven G. Meuth dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 14 · 2021 · Inggris · DOAJ Scopus

    The past decades have yielded major therapeutic advances in many autoimmune conditions – such as multiple sclerosis (MS) – and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy…

  5. Artikel Jurnal

    A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors

    Sinah Engel; Lara S Molina Galindo; Stefan Bittner dkk.

    Journal of Central Nervous System Disease, Vol. 13 · 2021 · Inggris · DOAJ Scopus

    Progressive multifocal leukoencephalopathy (PML) is a potentially fatal condition caused by a brain infection with JC polyomavirus (JCV), which occurs almost exclusively in immunocompromised patients. Modern immunosuppressive and immunomodulatory treatments for cancers and autoimmune diseases have…

  6. Artikel Jurnal

    Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosisResearch in context

    Muriel Schraad; Timo Uphaus; Stefan Runkel dkk.

    EBioMedicine, Vol. 87 · 2023 · Inggris · DOAJ Scopus

    Summary: Background: Disease-modifying therapies (DMT) for multiple sclerosis (MS) influence SARS-CoV-2 vaccination response, which might have implications for vaccination regimens in individual patients. Expanding the knowledge of predictors for an insufficient vaccination response as a surrogate…

  7. Artikel Jurnal

    Atypical adverse events in a real-world study of long-term immunomodulation for multiple sclerosis and neuromyelitis optica spectrum disorder

    Amelie Kirschbaum; Felix Luessi; Arda Civelek dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 18 · 2025 · Inggris · DOAJ Scopus

    Background: Immunotherapies are integral in managing multiple sclerosis (MS) and related demyelinating diseases, but adverse drug reactions significantly affect the tolerability of disease-modifying therapies (DMTs). Objectives: This study aims to assess the safety profile of DMTs within a…

  8. Artikel Jurnal

    Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

    Katrin Pape; Maria Protopapa; Muriel Schraad dkk.

    Frontiers in Oncology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    BackgroundCombination treatment with BRAF/MEK inhibitors favorably impact progression-free survival in malignant melanoma. However, it may cause paradoxical activation of the MAPK/ERK pathway in immune cells without BRAF mutation, which may lead to over activation of the immune system, especially…

  9. Artikel Jurnal

    PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

    Sinah Engel; Felix Luessi; Aneka Mueller dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 13 · 2020 · Inggris · DOAJ Scopus

    Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to…

  10. Artikel Jurnal

    Neurons differentially upregulate type 2 immune cytokines and interleukin-4 receptor subtypes during neuroinflammation

    Micaela Domingues; Yvonne Gärtner; Nicholas Hanuscheck dkk.

    Acta Neuropathologica Communications, Vol. 14 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Although numerous studies demonstrate beneficial effects of exogenous interleukin-4 (IL-4) in different central nervous system (CNS) disease models, little is known about the expression of IL-4 and its receptor (IL-4R) system in neurons. We previously showed that the beneficial effects of…

  11. Artikel Jurnal Teks lengkap

    Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation

    Katja Herges; Jason M. Millward; Nicole Hentschel dkk.

    PLoS ONE, Vol. 6 No. 10 · 2011 · Inggris · PLOS Scopus

    Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system. However, studies of MS and the animal model, experimental autoimmune encephalomyelitis (EAE), indicate that neuronal pathology is the principle cause of clinical disability. Thus, there is need to develop…

    Juga tersedia di: DOAJ

  12. Artikel Jurnal

    The frequency of follicular T helper cells differs in acute and chronic neuroinflammation

    Adalie Baniahmad; Katharina Birkner; Johanna Görg dkk.

    Scientific Reports, Vol. 10 No. 1 · 2020 · Inggris · DOAJ Scopus

    Abstract Beyond the major role of T cells in the pathogenesis of the autoimmune neuroinflammatory disorder multiple sclerosis (MS), recent studies have highlighted the impact of B cells on pathogenic inflammatory processes. Follicular T helper cells (Tfh) are essential for the promotion of B…

  13. Artikel Jurnal Teks lengkap

    Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis—A Real-World Scenario

    Muriel Schraad; Stefan Runkel; Walter Hitzler dkk.

    Vaccines, Vol. 12 No. 3 · 2024 · Inggris · DOAJ Scopus

    Immunomodulatory and immunosuppressive therapy is needed in people with a chronic neuroinflammatory disease of the central nervous system such as multiple sclerosis (MS). Therefore, MS requires monitoring for and preventing against infectious diseases like SARS-CoV-2. Vaccination and anti-viral…

  14. Artikel Jurnal

    Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis

    Maria Protopapa; Samantha Schmaul; Muriel Schraad dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 17 · 2024 · Inggris · DOAJ Scopus

    Background: Interferon-beta (IFN-β) still plays a fundamental role in immunomodulation of people with multiple sclerosis (MS) with low disease activity and in clinically isolated syndrome (CIS). In 2014, pegylated (PEG) interferon was licensed by the European Medicines Agency (EMA) for…

  15. Artikel Jurnal

    Real world observation of fatigue in multiple sclerosis comparing self-guided online cognitive behavioral therapy versus psychoeducation

    Maria Protopapa; Jana Samarin; Muriel Schraad dkk.

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 12 · 2026 · Inggris · DOAJ Scopus

    Background Fatigue is a common symptom in people with multiple sclerosis (pwMS) with severe implications. A self-guided, internet-based intervention to reduce fatigue in MS, based on cognitive behavioral therapy (CBT), is approved as a digital health application (DiGA) in the German healthcare…

  16. Artikel Jurnal Teks lengkap

    MRI Pattern Recognition in Multiple Sclerosis Normal-Appearing Brain Areas

    Martin Weygandt; Kerstin Hackmack; Caspar Pfüller dkk.

    PLoS ONE, Vol. 6 No. 6 · 2011 · Inggris · PLOS Scopus

    Objective: Here, we use pattern-classification to investigate diagnostic information for multiple sclerosis (MS; relapsing­remitting type) in lesioned areas, areas of normal­appearing grey matter (NAGM), and normal-appearing white matter (NAWM) as measured by standard MR techniques. Methods: A…

  17. Artikel Jurnal Teks lengkap

    Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis

    Bettina Trinschek; Felix Lüssi; Jürgen Haas dkk.

    PLoS ONE, Vol. 8 No. 10 · 2013 · Inggris · PLOS Scopus

    In multiple sclerosis (MS) autoaggressive T effector cells (Teff) are not efficiently controlled by regulatory T cells (Treg) but the underlying mechanisms are incompletely understood. Proinflammatory cytokines are key factors facilitating Teff activity in chronic inflammation. Here we investigated…